Trans-placental passage of methylglucamine diatrizoate was studied in 11 human fetuses after intravenous injection to the mother 5 to 49 minutes prior to abortion by hysterotomy. The contrast medium passed the placental barrier and was detected in all fetal tissues measured. No evidence was found of selective uptake by any fetal tissue. The hazards of fetal exposure should be taken into consideration before the administration of intravascular radiographic contrast agents to pregnant women.
We compared the survival of women diagnosed with invasive lobular carcinoma subtypes prior to and during the mammography screening era to determine the impact of early detection and treatment in an early phase upon survival according to tumor subtypes. Using mammographic tumor features, we classified 428 consecutive invasive lobular carcinoma cases of the breast into four subgroups according to their mammographic tumor features.Life-table-based survival curves and adjusted survival curves with the accelerated failure time method were plotted to demonstrate the 14-year follow-up survival outcome with adjustment for tumor size, node status, histologic malignancy grade, tumor focality and treatment. Survival of invasive lobular carcinoma subtypes was substantially improved as a result of early detection through mammography screening and treatment in an early phase, except for the subtype presenting as architectural distortion on the mammogram, even with the use of modern therapeutic methods. There is a clear need to further develop diagnostic and management strategies to decrease mortality from the diffusely infiltrating special subtype of invasive lobular carcinoma.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.